Bovalto Ibraxion

RSS

Infectious bovine rhinotracheitis vaccine (inactivated)

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Bovalto Ibraxion has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 13/08/2019

Authorisation details

Product details
Name
Bovalto Ibraxion
Agency product number
EMEA/V/C/000051
Active substance
inactivated IBR virus
International non-proprietary name (INN) or common name
Infectious bovine rhinotracheitis vaccine (inactivated)
Species
Cattle
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI02AA03
Publication details
Marketing-authorisation holder
Merial
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
09/03/2000
Contact address

29 Avenue Tony Garnier
69007 Lyon
France

Product information

10/08/2016 Bovalto Ibraxion - EMEA/V/C/000051 - IAIN/0016

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for bovidae

Therapeutic indication

Active immunisation of cattle to reduce the clinical signs of infectious bovine rhinotracheitis (IBR) and field virus excretion.
The onset of immunity is 14 days and the duration of immunity is 6 months.

Assessment history

How useful was this page?

Add your rating